See inside every stock. Pro
S&P 5007,624▼ 0.52%Nasdaq25,955▼ 0.21%Dow Jones52,215▼ 1.23%Nasdaq 10028,958▼ 0.00%VIX19.45▲ 2.21%US Dollar101.75▲ 0.14%Gold spot3,994▼ 0.75%WTI103.27▲ 3.82%
Euronext Paris · France · Updated after 23 Oct 2026 close

Inventiva S.A

IVA · Euronext Paris · prices in EUR
EUR 3.060▼ -0.045 (1.45%)
Research reportHistorical data

About Inventiva S.A

Inventiva is a clinical-stage biopharmaceutical company based in France that designs and develops oral small-molecule medicines for patients with fibrotic diseases and related conditions. Its work centres on compounds that act on nuclear receptors, with its main programme aimed at non-alcoholic steatohepatitis, a liver disease linked to fat accumulation and scarring. The company serves the pharmaceutical market through its own research pipeline and through partnerships with larger drugmakers, and it carries out laboratory and clinical development work from its base in France.

The shares are listed on the Euronext Paris in France under the code IVA, and the price on this page is in euros (EUR). Our records, which start in 2019, show no dividend payments for it. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.

34/ 100
Market X-Ray · price-based
Weak price profile
Ranks #475 of 625 on the Euronext Paris · confidence High
What this score is, and is not
It describes how this stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is. That fundamental X-Ray needs financial statements, which we do not have for France yet.
TrendWeak
19/100
Below its long-term averages and far from its highs.
See the numbers →
Above 200-day average-27.3%
From 52-week high-48.8%
MomentumWeak
31/100
Lagging most stocks on this exchange.
See the numbers →
3-month return-20.8%
6-month return-32.0%
12-month, skipping last month-3.4%
Stability (higher is calmer)Weak
24/100
Volatile, with deep drawdowns.
See the numbers →
Volatility, 1 year (lower is calmer)63.5%
Worst drawdown, 1 year (smaller is calmer)-55.8%
LiquidityStrong
82/100
Trades actively.
See the numbers →
Avg daily value traded1.71M EUR
Zero-volume days0.0%
IncomeNone
–/100
Pays no dividend.
See the numbers →
Years with dividends0
Price-based X-Ray. The fundamental X-Ray (financial health, valuation, growth, fair value) is available for US stocks today. It will follow for France when fundamentals data for this market is added. All France stocks.
Price trend
Below its 200-day average
Versus its 50- and 200-day averages
52-week range
2.570 – 6.200
Price is 13% of the way up
Returns
−20.8% 3m · −1.4% 1y
Price returns, dividends not included
RSI (14)
50
Neutral zone

Price chart

52-wk range 2.570 – 6.200 Daily closes, split-adjusted

Signals

50-day average3.398
200-day average4.210
Golden/death cross (60d)None
New 52-week highNo
Bullish RSI divergenceYes
Average daily range (ATR)0.223

Technical summary

Daily
Neutral
5 bullish · 4 neutral · 7 bearish
Weekly
Strongly bearish
0 bullish · 1 neutral · 11 bearish
Monthly
Strongly bearish
0 bullish · 1 neutral · 7 bearish
Moving averages (daily)
SMA 102.87Bullish
EMA 102.95Bullish
SMA 202.93Bullish
EMA 202.99Bullish
SMA 503.40Bearish
EMA 503.25Bearish
SMA 1003.50Bearish
EMA 1003.54Bearish
SMA 2004.21Bearish
EMA 2003.77Bearish
Oscillators (daily)
RSI (14)50.21Neutral
MACD (12, 26)-0.10Bearish
Momentum (12)2.68Bullish
Stochastic %K (14)76.56Neutral
Williams %R (14)-23.44Neutral
CCI (20)84.32Neutral
Pivot points (classic, last session)
S3
2.85
S2
2.94
S1
3.00
Pivot
3.09
R1
3.15
R2
3.24
R3
3.30
Signals describe what the chart is doing, not what to do. Moving averages: price above the average is bullish. Oscillators use the usual thresholds (RSI 30/70, Stochastic 20/80, CCI ±100, Williams %R −80/−20; MACD and momentum above zero are bullish). Weekly and monthly views use closing prices only.

Prices are end-of-day closes in EUR. Educational only, not financial advice.